Your browser doesn't support javascript.
Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.
Dispinseri, Stefania; Secchi, Massimiliano; Pirillo, Maria Franca; Tolazzi, Monica; Borghi, Martina; Brigatti, Cristina; De Angelis, Maria Laura; Baratella, Marco; Bazzigaluppi, Elena; Venturi, Giulietta; Sironi, Francesca; Canitano, Andrea; Marzinotto, Ilaria; Tresoldi, Cristina; Ciceri, Fabio; Piemonti, Lorenzo; Negri, Donatella; Cara, Andrea; Lampasona, Vito; Scarlatti, Gabriella.
  • Dispinseri S; Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Secchi M; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Pirillo MF; DNA Enzymology & Molecular Virology Unit, Institute of Molecular Genetics, National Research Council, Pavia, Italy.
  • Tolazzi M; National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
  • Borghi M; Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Brigatti C; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • De Angelis ML; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Baratella M; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Bazzigaluppi E; Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Venturi G; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Sironi F; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Canitano A; Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Marzinotto I; National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
  • Tresoldi C; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Ciceri F; Molecular Hematology Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Piemonti L; Hematology and Bone Marrow Transplantation Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Negri D; School of Medicine and Surgery, Università Vita-Salute San Raffaele, Milan, Italy.
  • Cara A; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Lampasona V; School of Medicine and Surgery, Università Vita-Salute San Raffaele, Milan, Italy.
  • Scarlatti G; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Nat Commun ; 12(1): 2670, 2021 05 11.
Article in English | MEDLINE | ID: covidwho-1225507
ABSTRACT
Understanding how antibody responses to SARS-CoV-2 evolve during infection may provide important insight into therapeutic approaches and vaccination for COVID-19. Here we profile the antibody responses of 162 COVID-19 symptomatic patients in the COVID-BioB cohort followed longitudinally for up to eight months from symptom onset to find SARS-CoV-2 neutralization, as well as antibodies either recognizing SARS-CoV-2 spike antigens and nucleoprotein, or specific for S2 antigen of seasonal beta-coronaviruses and hemagglutinin of the H1N1 flu virus. The presence of neutralizing antibodies within the first weeks from symptoms onset correlates with time to a negative swab result (p = 0.002), while the lack of neutralizing capacity correlates with an increased risk of a fatal outcome (p = 0.008). Neutralizing antibody titers progressively drop after 5-8 weeks but are still detectable up to 8 months in the majority of recovered patients regardless of age or co-morbidities, with IgG to spike antigens providing the best correlate of neutralization. Antibody responses to seasonal coronaviruses are temporarily boosted, and parallel those to SARS-CoV-2 without dampening the specific response or worsening disease progression. Our results thus suggest compromised immune responses to the SARS-CoV-2 spike to be a major trait of COVID-19 patients with critical conditions, and thereby inform on the planning of COVID-19 patient care and therapy prioritization.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-22958-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-22958-8